Druggable cavities and allosteric modulators of the cell division cycle 7 (CDC7) kinase

References

• Hartwell LH, Culotti J, Pringle JR, Reid BJ. Genetic control of the cell division cycle in yeast. Science. 1974;183(4120):46–51.
   PubMed Web of Science ®Google Scholar
• Kim JM, Yamada M, Masai H. Functions of mammalian Cdc7 kinase in initiation/monitoring of DNA replication and development. Mutat Res. 2003;532(1-2):29–40.
   PubMed Web of Science ®Google Scholar
• Kitamura R, Fukatsu R, Kakusho N, Cho YS, Taniyama C, Yamazaki S, Toh GT, Yanagi K, Arai N, Chang HJ, et al. Molecular mechanism of activation of human Cdc7 kinase: bipartite interaction with Dbf4/activator of S phase kinase (ASK) activation subunit stimulates ATP binding and substrate recognition. J Biol Chem. 2011;286(26):23031–23043.
   PubMed Web of Science ®Google Scholar
• Guo Y, Wang J, Benedict B, Yang C, van Gemert F, Ma X, Gao D, Wang H, Zhang S, Lieftink C, et al. Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer. Genome Med. 2021;13(1):166.
   PubMed Web of Science ®Google Scholar
• Choschzick M, Lebeau A, Marx AH, Tharun L, Terracciano L, Heilenkötter U, Jaenicke F, Bokemeyer C, Simon R, Sauter G, et al. Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer. Hum Pathol. 2010;41(3):358–365.
   PubMed Web of Science ®Google Scholar
• Melling N, Muth J, Simon R, Bokemeyer C, Terracciano L, Sauter G, Izbicki JR, Marx AH. Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer. Diagn Pathol. 2015;10(1):125.
   PubMedGoogle Scholar
• Liu R, Huang Y. CDC7 as a novel biomarker and druggable target in cancer. Clin Transl Oncol. 2022;24(10):1856–1864.
   PubMed Web of Science ®Google Scholar
• Deng L, Yang L, Zhu S, Li M, Wang Y, Cao X, Wang Q, Guo L. Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening. Cell Death Discov. 2023;9(1):40.
   PubMed Web of Science ®Google Scholar
• Tsuji T, Ficarro SB, Jiang W. Essential role of phosphorylation of MCM2 by Cdc7/Dbf4 in the initiation of DNA replication in mammalian cells. Mol Biol Cell. 2006;17(10):4459–4472.
   PubMed Web of Science ®Google Scholar
• Liachko NF, McMillan PJ, Guthrie CR, Bird TD, Leverenz JB, Kraemer BC. CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. Ann Neurol. 2013;74(1):39–52.
   PubMed Web of Science ®Google Scholar
• Vaca G, Martinez-Gonzalez L, Fernandez A, Rojas-Prats E, Porras G, Cuevas EP, Gil C, Martinez A, Martin-Requero A. Therapeutic potential of novel cell division cycle kinase 7 inhibitors on TDP-43-related pathogenesis such as frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). J Neurochem. 2021;156(3):379–390.
   PubMed Web of Science ®Google Scholar
• Rojas-Prats E, Martinez-Gonzalez L, Gonzalo-Consuegra C, Liachko NF, Perez C, Ramirez D, Kraemer BC, Martin-Requero A, Perez DI, Gil C, et al. Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: a new therapeutic approach for amyotrophic lateral sclerosis. Eur J Med Chem. 2021;210:112968.
   PubMed Web of Science ®Google Scholar
• Li W, Zhao XL, Shang SQ, Shen HQ, Chen X. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 suppresses hepatocarcinoma synergistically with 5-Fluorouracil. Curr Cancer Drug Targets. 2015;15(3):196–204.
   PubMed Web of Science ®Google Scholar
• Koltun ES, Tsuhako AL, Brown DS, Aay N, Arcalas A, Chan V, Du H, Engst S, Ferguson K, Franzini M, et al. Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorg Med Chem Lett. 2012;22(11):3727–3731.
   PubMed Web of Science ®Google Scholar
• Wodak SJ, Paci E, Dokholyan NV, Berezovsky IN, Horovitz A, Li J, Hilser VJ, Bahar I, Karanicolas J, Stock G, et al. Allostery in its many disguises: from theory to applications. Structure. 2019;27(4):566–578.
   PubMed Web of Science ®Google Scholar
• To C, Beyett TS, Jang J, Feng WW, Bahcall M, Haikala HM, Shin BH, Heppner DE, Rana JK, Leeper BA, et al. An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nat Cancer. 2022;3(4):402–417.
   PubMedGoogle Scholar
• Roskoski R. Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update. Pharmacol Res. 2023;187:106552.
   PubMed Web of Science ®Google Scholar
• Lu X, Smaill JB, Ding K. new promise and opportunities for allosteric kinase inhibitors. Angew Chem Int Ed Engl. 2020;59(33):13764–13776.
   PubMed Web of Science ®Google Scholar
• Cheng AN, Lo YK, Lin YS, Tang TK, Hsu CH, Hsu JT, Lee AY. Identification of Novel Cdc7 Kinase Inhibitors as anti-cancer agents that target the interaction with Dbf4 by the fragment complementation and drug repositioning approach. EBioMedicine. 2018;36:241–251.
   PubMed Web of Science ®Google Scholar
• Sebastián-Pérez V, Roca C, Awale M, Reymond J-L, Martinez A, Gil C, Campillo NE. Medicinal and biological chemistry (MBC) library: an efficient source of new hits. J Chem Inf Model. 2017;57(9):2143–2151.
   PubMed Web of Science ®Google Scholar
• Le Guilloux V, Schmidtke P, Tuffery P. Fpocket: an open source platform for ligand pocket detection. BMC Bioinformatics. 2009;10(1):168.
   PubMedGoogle Scholar
• Hughes S, Elustondo F, Di Fonzo A, Leroux FG, Wong AC, Snijders AP, Matthews SJ, Cherepanov P. Crystal structure of human CDC7 kinase in complex with its activator DBF4. Nat Struct Mol Biol. 2012;19(11):1101–1107.
   PubMed Web of Science ®Google Scholar
• Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013;27(3):221–234.
   PubMed Web of Science ®Google Scholar
• Schrödinger LLC. Schrödinger Suite including LigPrep, Protein Preparation Wizard, Epik, Impact, and Prime. New York; 2017.
   Google Scholar
• Harder E, Damm W, Maple J, Wu C, Reboul M, Xiang JY, Wang L, Lupyan D, Dahlgren MK, Knight JL, et al. OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. J Chem Theory Comput. 2016;12(1):281–296.
   PubMed Web of Science ®Google Scholar
• Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739–1749.
   PubMed Web of Science ®Google Scholar
• Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem. 2004;47(7):1750–1759.
   PubMed Web of Science ®Google Scholar
• Greenidge PA, Kramer C, Mozziconacci JC, Sherman W. Improving docking results via reranking of ensembles of ligand poses in multiple X-ray protein conformations with MM-GBSA. J Chem Inf Model. 2014;54(10):2697–2717.
   PubMed Web of Science ®Google Scholar
• Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov. 2015;10(5):449–461.
   PubMed Web of Science ®Google Scholar
• Mena-Ulecia K, Tiznado W, Caballero J. Study of the differential activity of thrombin inhibitors using docking, QSAR, molecular dynamics, and MM-GBSA. PLOS One. 2015;10(11):e0142774.
   PubMed Web of Science ®Google Scholar
• Dukka BK. Structure-based methods for computational protein functional site prediction. Comput Struct Biotechnol J. 2013;8(11):e201308005.
   PubMedGoogle Scholar
• Jiang W, McDonald D, Hope TJ, Hunter T. Mammalian Cdc7-Dbf4 protein kinase complex is essential for initiation of DNA replication. Embo J. 1999;18(20):5703–5713.
   PubMed Web of Science ®Google Scholar
• Jones DR, Prasad AA, Chan PK, Duncker BP. The Dbf4 motif C zinc finger promotes DNA replication and mediates resistance to genotoxic stress. Cell Cycle. 2010;9(10):2018–2026.
   PubMed Web of Science ®Google Scholar
• Ogino K, Takeda T, Matsui E, Iiyama H, Taniyama C, Arai K, Masai H. Bipartite binding of a kinase activator activates Cdc7-related kinase essential for S phase. J Biol Chem. 2001;276(33):31376–31387.
   PubMed Web of Science ®Google Scholar
• Modi V, Dunbrack RL. Jr. A structurally-validated multiple sequence alignment of 497 human protein kinase domains. Sci Rep. 2019;9(1):19790.
   PubMedGoogle Scholar
• Salado IG, Redondo M, Bello ML, Perez C, Liachko NF, Kraemer BC, Miguel L, Lecourtois M, Gil C, Martinez A, et al. Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. J Med Chem. 2014;57(6):2755–2772.
   PubMed Web of Science ®Google Scholar
• Maestro I, Madruga E, Boya P, Martínez A. Identification of a new structural family of SGK1 inhibitors as potential neuroprotective agents. J Enzyme Inhib Med Chem. 2023;38(1):2153841.
   PubMed Web of Science ®Google Scholar
• Ginex T, Madruga E, Martinez A, Gil C. MBC and ECBL libraries: outstanding tools for drug discovery. Front Pharmacol. 2023;14:1244317.
   PubMed Web of Science ®Google Scholar
• Crooks GE, Hon G, Chandonia JM, Brenner SE. WebLogo: a sequence logo generator. Genome Res. 2004;14(6):1188–1190.
   PubMed Web of Science ®Google Scholar
• Hou T, Wang J, Li Y, Wang W. Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model. 2011;51(1):69–82.
   PubMed Web of Science ®Google Scholar